Will Chinese ovarian cancer patients benefit from knowing the BRCA2 mutation status?

Chinese Journal of Cancer

Volumn 31, Issue 1, 2012, Pages 1-4

  Liu, Guo Yan ^a,b   Zhang, Wei ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

BRCA mutation; Drug response; Ovarian cancer; Survival

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PLATINUM COMPLEX;

CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CHINA; CHINESE; EDITORIAL; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC COUNSELING; HUMAN; MUTATIONAL ANALYSIS; OVARIECTOMY; OVARY CANCER; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PREDICTION; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROPHYLAXIS; RISK ASSESSMENT; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE;

AGE FACTORS; ASIAN CONTINENTAL ANCESTRY GROUP; DISEASE-FREE SURVIVAL; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; MUTATION; OVARIAN NEOPLASMS; PLATINUM; REMISSION INDUCTION; RISK; SURVIVAL RATE;

EID: 84862942053     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.011.10432     Document Type: Editorial

References (25)

1. Sowter HM, Ashworth A. BRCA1 and BRCA2 as ovarian cancer susceptibility genes. Carcinogenesis, 2005,26(10):1651-1656.
2. National Office for Cancer Prevention and Control, National Center for Cancer Registry, Disease Prevention and Control Bureau, MOH. Chinese cancer registry annual report (2004). Beijing: Peking Union Medical College Press, 2008:10.
3. Shen K, Lang JH, Huang LR, et al. Diagnosis and management strategies of hereditary ovarian cancer syndrome. Chin J Obstet Gynecol, 1996,31(12):732-735. [in Chinese]
4. Shi YR, Niu RF, Wei XY, et al. Investigation and analyses of family history of 144 patients with ovarian cancer. Chin J Obstet Gynecol, 2004,39(4):269-270. [in Chinese]
5. Li N, Wu LY, Zhang R, et al. Clinical analysis of 91 cases of hereditary breast and ovarian cancer. Chin J Oncol, 2005,27(4):245-247. [in Chinese]
6. Tang NLS, Pang CP, Yeo W, et al. Prevalence of mutations in the BRCA1 gene among Chinese patients with breast cancer. J Nat Cancer Inst, 1999,91(10):882-885.
7. Khoo US, Chan KY, Cheung AN, et al. Recurrent BRCA1 and BRCA2 germline mutations in ovarian cancer: a founder mutation of BRCA1 identified in the Chinese population. Hum Mutat, 2002,19(3):307-308.
8. Kwong A, Wong LP, Wong HN, et al. A BRCA2 founder mutation and seven novel deleterious BRCA mutations in southern Chinese women with breast and ovarian cancer. Breast Cancer Res Treat, 2009,117(3):683-636.
9. Sng JH, Chang J, Feroze F, et al. The prevalence of BRCA1 mutations in Chinese patients with early onset breast cancer and affected relatives. Br J Cancer, 2000,82(3):538-542.
10. Li SS, Tseng HM, Yang TP, et al. Molecular characterization of germline mutations in the BRCA1 and BRCA2 genes from breast cancer families in Taiwan. Hum Genet, 1999,104(3): 201-204.
11. Rao NY, Zhou J, Zhao L, et al. BRCA1 and BRCA2 deleterious mutation in 219 Han Chinese hereditary breast cancer patients. Chin Oncol, 2008,(5):370-375. [in Chinese]
12. Tao T. Research on BRCA1/2 mutations and its clinical importance in ovarian cancer patients from families at risk of hereditary ovarian cancer and patients with sporadic ovarian cancer. PhD thesis, 2010. [in Chinese]
13. Kwong A, Wong CH, Shea C, et al. Choice of management of southern Chinese BRCA mutation carriers. World J Surg, 2010,34(7):1416-1426.
14. Turner N, Tutt A, Ashworth A, et al. Hallmarks of "BRCAness" in sporadic cancers. Nat Rev Cancer, 2004,4(10):814-819.
15. Yang D, Khan S, Sun Y, et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA, 2011,306(14):1557-1565.
16. Pharoah PD, Easton DF, Stockton DL, et al. Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. Cancer Res, 1999,59(4):868-871.
17. Boyd J, Sonoda Y, Federici MG, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA, 2000,283(17): 2260-2265.
18. Ramus SJ, Fishman A, Pharoah PD, et al. Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations. Eur J Surg Oncol, 2001,27(3):278-281.
19. Cass I, Baldwin RL, Varkey T, et al. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer, 2003,97(9):2187-2195.
20. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 2005,434(7035):917-921.
21. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumors with inhibitors of poly (ADP-ribose) polymerase. Nature, 2005,447(7142):346.
22. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med, 2009,361(2):123-134.
23. Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet, 2010,376(9737):245-251.
24. Fong PC, Yap TA, Boss DS, et al. Poly (ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol, 2010,28(15):2512-2519.
25. Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-la bel, non-randomised study. Lancet Oncol, 2011,12(9):852-861.